RU2000131593A - SELECTIVE AGONISTS AND ANTAGONISTS IL-2. - Google Patents
SELECTIVE AGONISTS AND ANTAGONISTS IL-2.Info
- Publication number
- RU2000131593A RU2000131593A RU2000131593/04A RU2000131593A RU2000131593A RU 2000131593 A RU2000131593 A RU 2000131593A RU 2000131593/04 A RU2000131593/04 A RU 2000131593/04A RU 2000131593 A RU2000131593 A RU 2000131593A RU 2000131593 A RU2000131593 A RU 2000131593A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- mutant human
- 2rαβγ
- mutant
- replaced
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims 12
- 239000000556 agonist Substances 0.000 title 1
- 230000003042 antagnostic Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 101000018963 IL2 Proteins 0.000 claims 14
- 102000034277 human IL2 protein Human genes 0.000 claims 14
- 102000000588 Interleukin-2 Human genes 0.000 claims 11
- 210000004027 cells Anatomy 0.000 claims 8
- 229920000023 polynucleotide Polymers 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229960000310 ISOLEUCINE Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 229940009098 Aspartate Drugs 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 210000000987 Immune System Anatomy 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 229920000903 Polyhydroxyalkanoate Polymers 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000002147 killing Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (23)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 | |
US09/080,080 | 1998-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000131593A true RU2000131593A (en) | 2003-04-20 |
RU2235729C2 RU2235729C2 (en) | 2004-09-10 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000131593/04A RU2235729C2 (en) | 1998-05-15 | 1999-05-13 | Selective agonists and antagonists of il-2 |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (en) |
JP (1) | JP4276783B2 (en) |
KR (1) | KR100607609B1 (en) |
CN (2) | CN100366742C (en) |
AR (1) | AR020322A1 (en) |
AT (1) | ATE351907T1 (en) |
AU (1) | AU759697B2 (en) |
BG (1) | BG65139B1 (en) |
BR (1) | BRPI9910504B1 (en) |
CA (1) | CA2327349C (en) |
CO (1) | CO5070701A1 (en) |
CU (2) | CU23273B7 (en) |
CY (1) | CY1107533T1 (en) |
CZ (1) | CZ302071B6 (en) |
DE (1) | DE69934881T2 (en) |
DK (1) | DK1076704T3 (en) |
DZ (1) | DZ2788A1 (en) |
ES (1) | ES2281175T3 (en) |
HK (1) | HK1039963B (en) |
HN (1) | HN1999000075A (en) |
HU (1) | HU226142B1 (en) |
IL (2) | IL139136A0 (en) |
MY (1) | MY130274A (en) |
NO (1) | NO329235B1 (en) |
NZ (1) | NZ508098A (en) |
PA (1) | PA8472601A1 (en) |
PE (1) | PE20000475A1 (en) |
PL (1) | PL201675B1 (en) |
PT (1) | PT1076704E (en) |
RO (1) | RO122150B1 (en) |
RU (1) | RU2235729C2 (en) |
SI (1) | SI20643B (en) |
SK (1) | SK288100B6 (en) |
SV (1) | SV1999000061A (en) |
TN (1) | TNSN99090A1 (en) |
TR (1) | TR200003354T2 (en) |
TW (1) | TWI223663B (en) |
UA (1) | UA73719C2 (en) |
WO (1) | WO1999060128A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058456A2 (en) * | 1999-03-30 | 2000-10-05 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
RU2312677C9 (en) * | 2001-12-04 | 2008-03-27 | Мерк Патент Гмбх | Immunocytokines possessing modulated selectivity |
US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE602004031681D1 (en) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunctional cytokines |
DE602004031341D1 (en) | 2003-07-21 | 2011-03-24 | Transgene Sa | MULTIFUNCTIONAL CYTOKINE |
ES2346977T3 (en) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | THERAPY PROCEDURE FOR CANCERES THAT EXPRESS THE ANTIGEN CD40. |
US7858081B2 (en) * | 2004-02-27 | 2010-12-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutants having agonists/antagonists activity |
WO2005091956A2 (en) * | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN101244261B (en) * | 2008-03-10 | 2010-09-15 | 山东大学 | Biological agent containing non-renaturation recombinant protein, preparation method and application thereof |
DE102008023820A1 (en) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells |
JP5766124B2 (en) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | Compositions and methods for the treatment of inflammatory and autoimmune diseases |
CN102101885B (en) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | Human interleukin-II mutant of low-inductivity suppressor T cells and use thereof |
CU23923B1 (en) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY |
PL2637694T3 (en) | 2010-11-12 | 2021-10-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
CA2860170C (en) * | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
SI3489255T1 (en) | 2011-02-10 | 2021-11-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
WO2015042707A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-2 fusion proteins and uses thereof |
NZ719654A (en) | 2014-02-06 | 2020-06-26 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
KR20170035910A (en) * | 2014-08-11 | 2017-03-31 | 데리니아, 인크. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
WO2017201432A2 (en) * | 2016-05-19 | 2017-11-23 | Jounaidi Youssef | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
AU2017281469B2 (en) | 2016-06-22 | 2023-08-31 | David Klatzmann | Genetically modified T lymphocytes |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
KR20190094222A (en) * | 2016-12-13 | 2019-08-12 | 데리니아, 인크. | Multivalent Regulatory T Cell Modulators |
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
WO2018215938A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JOP20190271A1 (en) * | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
JP7433051B2 (en) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Uses and methods of IL-2 superagonists, agonists, and fusions thereof |
NZ761434A (en) * | 2017-08-03 | 2024-03-22 | Synthorx Inc | Cytokine conjugates for the treatment of autoimmune diseases |
KR20200086722A (en) * | 2017-11-21 | 2020-07-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Partial agonists of interleukin-2 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
MX2020006322A (en) | 2017-12-19 | 2020-09-18 | Xencor Inc | Engineered il-2 fc fusion proteins. |
EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
MX2020009857A (en) | 2018-03-28 | 2021-01-08 | Ascendis Pharma Oncology Div A/S | Il-2 conjugates. |
KR20200136453A (en) | 2018-03-28 | 2020-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | Interleukin-2/interleukin-2 receptor alpha fusion protein and method of use |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
MX2021000801A (en) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Il2 agonists. |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
CA3086486A1 (en) * | 2018-09-17 | 2020-03-26 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
US20220056094A1 (en) | 2018-12-21 | 2022-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Human interleukin-2 variant or derivative thereof |
JP2022533702A (en) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM-targeted immune tolerance |
TW202115105A (en) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2 agonists |
JP2022544236A (en) * | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | Interleukin-2 muteins for proliferation of regulatory T cells |
IL293628A (en) | 2019-12-12 | 2022-08-01 | Iltoo Pharma | Interleukin 2 chimeric constructs |
JP2023507115A (en) | 2019-12-17 | 2023-02-21 | アムジエン・インコーポレーテツド | Dual interleukin-2/TNF receptor agonist for use in therapy |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
EP4090674A4 (en) | 2020-01-14 | 2024-01-24 | Synthekine Inc | Biased il2 muteins methods and compositions |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
CA3175717A1 (en) | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
KR102545250B1 (en) * | 2020-03-31 | 2023-06-21 | 한미약품 주식회사 | Novel immunostimulating IL-2 analogs |
MX2022014082A (en) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Il-2 sequences and uses thereof. |
CN114507643A (en) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell derivative for expressing IL-2 and application thereof |
IL302114A (en) | 2020-10-29 | 2023-06-01 | Bristol Myers Squibb Co | Fusion proteins for the treatment of disease |
CN113308477A (en) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | Eukaryotic expression recombinant plasmid of duck IL-2 gene and preparation method thereof |
TW202320862A (en) | 2021-09-22 | 2023-06-01 | 大陸商信達生物製藥(蘇州)有限公司 | Il-2 mutein and the fusion protein thereof |
CA3233644A1 (en) | 2021-10-06 | 2023-04-13 | David Klatzmann | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
CN114875069B (en) * | 2022-04-22 | 2023-09-15 | 四川大学 | Recombinant vector of genetically modified IL2 cytokine, host cell and application thereof |
US20240076343A1 (en) * | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (en) | 2022-10-03 | 2024-04-05 | Arkema France | PROCESS FOR GRANULATING AZO COMPOUNDS AND GRANULES OBTAINED |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/en active
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/en not_active IP Right Cessation
- 1999-05-13 PL PL344407A patent/PL201675B1/en unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/en unknown
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/en not_active IP Right Cessation
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/en unknown
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/en not_active IP Right Cessation
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/en unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 CN CNB998086509A patent/CN100366742C/en not_active Expired - Lifetime
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/en not_active Application Discontinuation
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/en not_active IP Right Cessation
- 1999-05-13 DE DE69934881T patent/DE69934881T2/en not_active Expired - Lifetime
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/en unknown
- 1999-05-13 DK DK99924232T patent/DK1076704T3/en active
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/en active
- 1999-05-13 UA UA2000127206A patent/UA73719C2/en unknown
- 1999-05-13 HU HU0101948A patent/HU226142B1/en unknown
- 1999-05-13 IL IL13913699A patent/IL139136A0/en unknown
- 1999-05-13 RO ROA200001123A patent/RO122150B1/en unknown
- 1999-05-13 ES ES99924232T patent/ES2281175T3/en not_active Expired - Lifetime
- 1999-05-13 AR ARP990102269A patent/AR020322A1/en active IP Right Grant
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/en not_active Expired - Lifetime
- 1999-05-13 SI SI9920034A patent/SI20643B/en active Search and Examination
- 1999-05-13 AT AT99924232T patent/ATE351907T1/en active
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/en not_active Expired - Lifetime
- 1999-05-14 CO CO99030158A patent/CO5070701A1/en unknown
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/en active IP Right Grant
- 1999-05-14 TW TW088107812A patent/TWI223663B/en not_active IP Right Cessation
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/en unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/en unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/en not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/en not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/en not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/en not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000131593A (en) | SELECTIVE AGONISTS AND ANTAGONISTS IL-2. | |
CA2327349A1 (en) | Il-2 selective agonists and antagonists | |
EP1589990B1 (en) | Il-21 for use in treating cancer | |
NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
Kelker et al. | Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin | |
Chouaib et al. | Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. | |
RU98120519A (en) | AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES | |
PT593754E (en) | PEPTIDES OF HUMAN PAPILOMA VIRUS FOR USE IN INDUCTIVE COMPOSITIONS OF A T-CELL REACTION IN MAN | |
EP0240975A2 (en) | Human gamma interferon-specific receptor protein, antibody against said protein, methods for obtaining said protein and said antibody and compositions containing said protein and antibody | |
AU2011328688A1 (en) | Polypeptides derived from IL-2 having agonist activity, for the therapy of cancer and chronic infections | |
JP2005530716A5 (en) | ||
CN110935025A (en) | Agents for treating and/or preventing autoimmune diseases and for forming regulatory T cells | |
DE69837996D1 (en) | TUMOR NECROSE FACTOR RECEPTORS 6 ALPHA & 6 BETA | |
CA2150249A1 (en) | Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof | |
Stauber et al. | Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-β) on a human histiocytic lymphoma cell line, U-937 | |
Baxevanis et al. | Prothymosin alpha enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation. | |
Allegretta et al. | The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2) | |
GB8912651D0 (en) | Peptide fragments of hiv | |
CA2265885A1 (en) | Pharmaceutical compositions for the treatment of immune disorders | |
Papanastasiou et al. | Promotion of murine antitumour activity by prothymosin α treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor α | |
Sondel | Cellular immunotherapy of cancer: preclinical and clinical testing utilizing interleukin-2 | |
Mavligit | Immunologic effects of cimetidine: potential uses | |
EA200100395A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT | |
Bahn | Cytokines in thyroid eye disease: potential for anticytokine therapy | |
CA2397267A1 (en) | Peptide fragments and uses thereof as type-1 interferon antagonist |